# A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

> **NCT06132893** · PHASE2,PHASE3 · RECRUITING · sponsor: **Biohaven Therapeutics Ltd.** · enrollment: 390 (estimated)

## Conditions studied

- Focal Epilepsy

## Interventions

- **DRUG:** BHV-7000
- **DRUG:** BHV-7000
- **DRUG:** Placebo
- **DRUG:** BHV-7000
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06132893
- **Lead sponsor:** Biohaven Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-14
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132893, "A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06132893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*